Quarterly report · Q2
9627.TEDINET S100SH2U
Period2023-05-01 → 2023-10-31
Filed2023-12-15
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥193.7bn | 2023-05-01 → 2023-10-31 | Cons. | Net sales |
| Revenue | ¥358.7bn | 2022-05-01 → 2023-04-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥171.2bn | 2022-05-01 → 2022-10-31 | Cons. | Net sales |
| Operating income | ¥8.7bn | 2023-05-01 → 2023-10-31 | Cons. | Operating income |
| Operating income | ¥6.8bn | 2022-05-01 → 2022-10-31 | Cons. | Operating income |
| Ordinary income | ¥9.3bn | 2023-05-01 → 2023-10-31 | Cons. | Ordinary income |
| Ordinary income | ¥17.1bn | 2022-05-01 → 2023-04-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.3bn | 2022-05-01 → 2022-10-31 | Cons. | Ordinary income |
| Profit before tax | ¥9.4bn | 2023-05-01 → 2023-10-31 | Cons. | Income before income taxes |
| Profit before tax | ¥7.2bn | 2022-05-01 → 2022-10-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥5.3bn | 2023-05-01 → 2023-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥9.2bn | 2022-05-01 → 2023-04-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.8bn | 2022-05-01 → 2022-10-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥5.2bn | 2023-05-01 → 2023-10-31 | Cons. | Profit loss |
| Net income | ¥3.8bn | 2022-05-01 → 2022-10-31 | Cons. | Profit loss |
| Total assets | ¥242.9bn | at 2023-10-31 | Cons. | Assets |
| Total assets | ¥231.8bn | at 2023-04-30 | Cons. | Assets |
| Total assets | ¥231.3bn | at 2022-10-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥113.1bn | at 2023-10-31 | Cons. | Liabilities |
| Total liabilities | ¥105.2bn | at 2023-04-30 | Cons. | Liabilities |
| Net assets / equity | ¥129.8bn | at 2023-10-31 | Cons. | Net assets |
| Net assets / equity | ¥126.5bn | at 2023-04-30 | Cons. | Net assets |
| Net assets / equity | ¥120.9bn | at 2022-10-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥50.5bn | at 2023-10-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥46.8bn | at 2023-04-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥50.3bn | at 2023-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.2bn | at 2023-04-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥43.5bn | at 2022-10-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥59.5bn | at 2022-04-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥14.1bn | 2023-05-01 → 2023-10-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥20.3bn | 2022-05-01 → 2023-04-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.5bn | 2022-05-01 → 2022-10-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥5.8bn | 2023-05-01 → 2023-10-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥22.3bn | 2022-05-01 → 2023-04-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥18.6bn | 2022-05-01 → 2022-10-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥4.2bn | 2023-05-01 → 2023-10-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥11.2bn | 2022-05-01 → 2023-04-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥5.8bn | 2022-05-01 → 2022-10-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥149.66 | 2023-05-01 → 2023-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥88.73 | 2023-08-01 → 2023-10-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥262.87 | 2022-05-01 → 2023-04-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.32 | 2022-05-01 → 2022-10-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.78 | 2022-08-01 → 2022-10-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 53.4% | at 2023-10-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.6% | at 2023-04-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.2% | at 2022-10-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | revenue | 2023-05-01 → 2023-10-31 | ¥5.7bn |
| Otherother segments | revenue external | 2023-05-01 → 2023-10-31 | ¥5.7bn |
| Otherother segments | revenue intersegment | 2023-05-01 → 2023-10-31 | ¥24m |
| Otherother segments | segment ordinary income | 2023-05-01 → 2023-10-31 | −¥49m |
| Reconciling Itemsreconciling | revenue | 2023-05-01 → 2023-10-31 | −¥24m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-05-01 → 2023-10-31 | −¥24m |
| Reconciling Itemsreconciling | segment ordinary income | 2023-05-01 → 2023-10-31 | −¥4.4bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2023-05-01 → 2023-10-31 | ¥173.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2023-05-01 → 2023-10-31 | ¥173.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2023-05-01 → 2023-10-31 | ¥12.5bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2023-05-01 → 2023-10-31 | ¥14.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2023-05-01 → 2023-10-31 | ¥14.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2023-05-01 → 2023-10-31 | ¥1.3bn |
| —segment total | revenue | 2023-05-01 → 2023-10-31 | ¥193.8bn |
| —segment total | revenue external | 2023-05-01 → 2023-10-31 | ¥193.7bn |
| —segment total | revenue intersegment | 2023-05-01 → 2023-10-31 | ¥24m |
| —segment total | segment ordinary income | 2023-05-01 → 2023-10-31 | ¥13.8bn |
| Otherother segments | revenue | 2022-05-01 → 2022-10-31 | ¥5.8bn |
| Otherother segments | revenue external | 2022-05-01 → 2022-10-31 | ¥5.8bn |
| Otherother segments | revenue intersegment | 2022-05-01 → 2022-10-31 | ¥31m |
| Otherother segments | segment ordinary income | 2022-05-01 → 2022-10-31 | −¥18m |
| Reconciling Itemsreconciling | revenue | 2022-05-01 → 2022-10-31 | −¥31m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-05-01 → 2022-10-31 | −¥31m |
| Reconciling Itemsreconciling | segment ordinary income | 2022-05-01 → 2022-10-31 | −¥3.8bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue | 2022-05-01 → 2022-10-31 | ¥153.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | revenue external | 2022-05-01 → 2022-10-31 | ¥153.2bn |
| jpcrp040300-q2r_E04896-000Dispensing Pharmacyreportable segment | segment ordinary income | 2022-05-01 → 2022-10-31 | ¥10.8bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue | 2022-05-01 → 2022-10-31 | ¥12.2bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | revenue external | 2022-05-01 → 2022-10-31 | ¥12.2bn |
| jpcrp040300-q2r_E04896-000Drug And Cosmetic Storereportable segment | segment ordinary income | 2022-05-01 → 2022-10-31 | ¥349m |
| —segment total | revenue | 2022-05-01 → 2022-10-31 | ¥171.2bn |
| —segment total | revenue external | 2022-05-01 → 2022-10-31 | ¥171.2bn |
| —segment total | revenue intersegment | 2022-05-01 → 2022-10-31 | ¥31m |
| —segment total | segment ordinary income | 2022-05-01 → 2022-10-31 | ¥11.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 555
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes business combinations quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |